10-K: AbCellera Biologics Inc. Reports Full Year 2023 Results, Highlights Strategic Investments and Pipeline Progress

AbCellera Biologics Inc.'s 2023 annual report details strategic investments in technology and internal programs, alongside a diversified partnership portfolio, while navigating a shift from COVID-19 related revenues.

Summary

• AbCellera Biologics Inc. reported a net loss of $146.4 million for the year ended December 31, 2023, a significant shift from previous profitable years due to the absence of COVID-19 royalty revenues.
• The company has invested over $500 million in its antibody discovery and development engine and has over 40 partnerships and approximately 600 employees.
• AbCellera has generated over $250 million in cumulative earnings since 2012 and has approximately $1 billion in available liquidity as of December 31, 2023.
• The company is strategically leveraging its engine to develop internal programs, advancing two drug programs, ABCL635 and ABCL575, into IND-enabling studies.
• AbCellera secured CAD $300 million in non-dilutive financing from the Governments of Canada and British Columbia to build new capabilities and support the development of up to 17 internal programs through Phase 1 clinical trials.
• The company has 203 programs under contract with 46 unique partners, 87 of which include downstream participation in the form of milestones and royalty stakes.
• The global therapeutic antibody market is expected to grow to over $450 billion by 2028, with a compound annual growth rate of over 9%.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company is making strategic investments and advancing its pipeline, the significant net loss and shift away from COVID-19 revenues create uncertainty. The long-term potential is there, but the near-term outlook is challenging.

Positives

• AbCellera has a strong cash position with approximately $1 billion in available liquidity.
• The company is actively advancing its internal pipeline with two programs in IND-enabling studies.
• AbCellera has secured significant non-dilutive funding to support its growth and development.
• The company has a large and diversified portfolio of partnered programs, reducing risk.
• AbCellera is strategically investing in technology platforms to unlock new drug targets and modalities.

Negatives

• The company reported a net loss of $146.4 million in 2023, a significant shift from previous profitable years.
• AbCellera's royalty revenue decreased significantly due to the loss of COVID-19 related sales.
• The company expects to generate losses and negative operating cash flow in the near-to-medium term.

Risks

• The company may not be able to generate sufficient revenue to achieve profitability.
• AbCellera's quarterly and annual operating results may fluctuate significantly.
• The company's commercial success depends on the quality of its antibody discovery engine and its acceptance by partners.
• Development of biological molecules is inherently uncertain, and there is no guarantee of marketing approval or commercial success.
• The company may be unable to manage its current and future growth effectively.
• AbCellera faces significant competition in the life sciences technology market.
• Security breaches and loss of data could compromise sensitive information and expose the company to liability.

Future Outlook

The company expects to generate losses and negative operating cash flow in the near-to-medium term, a period of continued investments in its engine and internal programs, ahead of revenues generated from out licensingand milestone payments and royalties in the longer term. The company anticipates progressing AbCellera-initiated programs into selection of therapeutic antibody candidates for IND-enabling studies within the near-to-medium term. The company expects to complete its GMP facility and to have GMP manufacturing capabilities in use in 2025.

Management Comments

• The company believes that companies in its space should be evaluated not on the promise of their technology, but on the output of their platforms.
• AbCellera aspires to be recognized as the biotechnology industry's most powerful engine for antibody discovery and development, spanning the path from target to clinical testing.
• The company's strategy is based on two basic elements: building a competitive advantage in bringing antibody therapeutics from target into clinical testing and using its engine to work with strategic partners to build a large and diversified portfolio of royalty stakes.
• The company believes that its emphasis on milestone payments and royalty positions will result in stakes that substantially exceed in value the price it could command upfront for access to its engine.

Industry Context

The announcement highlights AbCellera's strategic shift from relying on pandemic-related revenues to focusing on long-term growth through technology development, internal programs, and diversified partnerships. This aligns with the broader industry trend of investing in innovative platforms and next-generation therapeutics, while also acknowledging the inherent risks and long timelines associated with drug development.

Comparison to Industry Standards

• AbCellera's approach of building an integrated engine for antibody discovery and development is a differentiated strategy compared to many CROs that offer point solutions or stand-alone instruments, such as WuXi Biologics Inc., Evotec SE, and Charles River Laboratories International, Inc.
• The company's focus on difficult targets like GPCRs and ion channels, and its T-cell engager platform, positions it to compete with companies like Adimab LLC, Twist Bioscience Corporation, and OmniAb, Inc., which also use proprietary platforms for antibody discovery.
• AbCellera's emphasis on downstream participation through milestones and royalties is a common practice in the biotechnology industry, but the company's increasing average royalty rates (from 2.4% to 4.3% between 2015-2019 and 2020-2023) suggest a growing ability to capture value from its partnerships.
• The company's investment in GMP manufacturing capabilities is a strategic move to integrate the entire drug development process, similar to some fully integrated CROs, but with a focus on its proprietary technology.
• The company's internal programs, such as ABCL635 and ABCL575, are aimed at addressing high-value therapeutic areas, which is a common strategy among biotechnology companies seeking to develop first-in-class or best-in-class medicines.

Legal Proceedings

• AbCellera is involved in ongoing patent litigation with Bruker Cellular Analysis.
• AbCellera is involved in a civil lawsuit with the Estate of John Schrader.

Stakeholder Impact

• Shareholders may experience volatility in the share price due to the company's shift in revenue streams and ongoing investments.
• Employees may experience changes in roles and responsibilities due to the company's restructuring and focus on internal programs.
• Partners may benefit from AbCellera's enhanced capabilities and integrated platform.
• Patients may benefit from the development of new antibody therapies through AbCellera's internal programs and partnerships.

Next Steps

• Complete the build of its facilities.
• Establish and validate fully-integrated capabilities to take programs from concept to the clinic.
• Support the development of up to 17 internal programs up to and through Phase 1 clinical trials.
• Progress AbCellera-initiated programs into selection of therapeutic antibody candidates for IND-enabling studies within the near-to-medium term.

Key Dates

Keywords

antibody discovery, drug development, biotechnology, therapeutic antibodies, clinical trials, partnerships, internal programs, milestone payments, royalty revenue, platform technology